(Q36292441)

13 August 2017

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen (English)

1 reference

13 August 2017

0 references

1 reference

Henriksson R

1

1 reference

13 August 2017

Nilsson S

2

1 reference

13 August 2017

Colleen S

3

1 reference

13 August 2017

Wersäll P

4

1 reference

13 August 2017

Helsing M

5

1 reference

13 August 2017

Zimmerman R

6

1 reference

13 August 2017

Engman K

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

8

1 reference

13 August 2017

1311-1317

1 reference

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Renal cell carcinoma and interleukin-2: a review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Spontaneous regression of genitourinary cancer--an update.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Hormonal therapy and chemotherapy of renal-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Tamoxifen potentiates in vivo antitumor activity of interleukin-2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150170

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

29 June 2018

1 reference

12 December 2020

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

12 December 2020

Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study

1 reference

12 December 2020

Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon

1 reference

12 December 2020

Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Renal cell cancer: is there long-term survival advantage from cytokine treatment?

1 reference

12 December 2020

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

12 December 2020

1 reference

12 December 2020

Combined interferon and vinblastine treatment in advanced renal cell cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.218

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

9579838

1 reference